Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs Zoetis Inc — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $29.12 (market cap $6.76B), while Zoetis Inc trades at $75.76 (market cap $30.70B). The key difference: Zoetis Inc is far larger — about 4.5× Janus Living Inc. Class A-1 Common Stock's market cap, and Zoetis Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Zoetis Inc for 71 Days on average.
| JAN | ZTS | |
|---|---|---|
Market Cap | $6.76B | $30.70B |
Volume | 1,332,082 | 3,299,421 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $147.53 |
52-Week Low | $22.88 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $6.85B | $38.27B |
Dividend Yield | 1.98% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Zoetis (ZTS) trades at $75.335, down 0.42% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported strong profitability with a 27.69% net income margin and 64.91% ROE for 2025, though Q1 2026 EPS missed expectations. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and industry-leading margins.
The outlook is cautiously optimistic, with a consensus price target of $87.33 implying 16% upside. Investment opportunities lie in Zoetis's robust fundamentals and market dominance, while risks include competitive pressures, weaker U.S. demand, and margin compression from promotions. The stock offers value at a P/E of 12.12, but investors should monitor Q3 2026 results for growth confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
